Predicting Adverse Events With Dabigatran or Warfarin in AFPredicting Adverse Events With Dabigatran or Warfarin in AF
This study examined various models that aim to quantify expected rates of thromboembolism and major bleeding for a given patient if that patient were to initiate treatment with dabigatran or warfarin British Medical Journal
Source: Medscape Critical Care Headlines - Category: Intensive Care Tags: Internal Medicine Journal Article Source Type: news
More News: Bleeding | Coumadin | Intensive Care | Internal Medicine | Pradaxa | Study | Thrombosis | Warfarin